ICCC
ImmuCell Corporation
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+31/100
Last price
9.97
▲ 0.22 (2.26%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
9.75
Day high
9.97
Day low
9.93
Volume
831
Market cap
$90.55M
P/E (TTM)
142.43
52W range
4.52 – 12.10
Trailing performance
Returnvs SPY
1W
+0.30%
-1.6%
1M
+0.71%
-0.4%
3M
-6.21%
-10.7%
6M
+51.06%
+32.9%
YTD
+62.11%
+47.9%
1Y
+58.00%
+41.6%
3Y
+86.70%
+4.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ICCC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.91M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | TE BOEKHORST PAUL FRANCIS OLIVIER Chief Executive Officer |
BUY | 8.00K | $75.96K | Direct |
| Mar 20, 26 | BRIGHAM MICHAEL F Director |
CONVERSION | 25.00K | $146.00K | Direct |
| Dec 4, 25 | TE BOEKHORST PAUL FRANCIS OLIVIER Chief Executive Officer |
BUY | 9.74K | $49.58K | Direct |
| Dec 3, 25 | TE BOEKHORST PAUL FRANCIS OLIVIER Chief Executive Officer |
BUY | 9.79K | $48.59K | Direct |
| Nov 25, 25 | TOMSCHE DAVID SCOTT Director |
BUY | 3.27K | $15.55K | |
| Jun 12, 25 | GATHAGAN BRYAN K Director |
BUY | 1.00K | $6.32K | Direct |
| Jun 11, 25 | BASSE GLORIA F Director |
CONVERSION | 3.53K | $16.98K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASSE GLORIA F |
Director | 3.53K | Conversion of Exercise of derivative security |
BRIGHAM MICHAEL F |
Director | 205.70K | Conversion of Exercise of derivative security |
GATHAGAN BRYAN K |
Director | 1.00K | Purchase |
TE BOEKHORST PAUL FRANCIS OLIVIER |
Chief Executive Officer | 17.79K | Purchase |
TOMSCHE DAVID SCOTT |
Director | — | Purchase |
Fundamentals
Market cap$90.55M
Enterprise value$94.14M
Revenue (TTM)$30.68M
Gross profit$12.37M
EBITDA$7.05M
Net income$787.37K
EPS (TTM)$0.07
Free cash flow$3.08M
Total cash$8.86M
Total debt$12.45M
Book value / share$3.46
Shares outstanding9.08M
Float6.03M
Short % of float0.26%
Dividend yield0.00%
Beta (5Y)0.57
Valuation & profitability ratios
Trailing P/E142.43
Forward P/E-90.64
PEG ratio—
Price / sales—
Price / book2.89
EV / revenue3.07
EV / EBITDA13.35
Gross margin40.32%
Operating margin26.93%
Profit margin2.57%
Return on equity2.57%
Return on assets6.25%
Debt / equity39.67
Current ratio4.75
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $27.64M | $26.49M | $17.47M | $18.57M | +4.3% |
| Operating revenue | $27.64M | $26.49M | $17.47M | $18.57M | +4.3% |
| Cost of revenue | $16.20M | $18.55M | $13.60M | $10.92M | -12.7% |
| Gross profit | $11.45M | $7.94M | $3.87M | $7.65M | +44.1% |
| Research & development | $3.04M | $3.90M | $4.39M | $4.49M | -22.0% |
| Selling, general & admin | $6.75M | $5.68M | $5.22M | $5.45M | +18.9% |
| Total operating expense | $9.80M | $9.58M | $9.62M | $9.95M | +2.2% |
| Operating income | $1.65M | -$1.64M | -$5.75M | -$2.30M | +200.6% |
| Net interest income | -$334.68K | -$491.02K | -$379.03K | -$195.44K | +31.8% |
| Pre-tax income | -$1.03M | -$2.15M | -$5.77M | -$2.49M | +52.1% |
| Tax provision | $11.57K | $10.06K | $4.63K | $7.67K | +15.1% |
| Net income | -$1.04M | -$2.16M | -$5.77M | -$2.49M | +51.8% |
| Net income to common | -$1.04M | -$2.16M | -$5.77M | -$2.49M | +51.8% |
| Basic EPS | -0.12 | -0.26 | -0.75 | -0.32 | +53.8% |
| Diluted EPS | -0.12 | -0.26 | -0.75 | -0.32 | +53.8% |
| EBIT | -$589.42K | -$1.62M | -$5.32M | -$2.14M | +63.6% |
| EBITDA | $2.14M | $1.07M | -$2.60M | $349.99K | +100.6% |
| Basic shares | 9.03M | 8.17M | 7.75M | 7.75M | +10.5% |
| Diluted shares | 9.03M | 8.17M | 7.75M | 7.75M | +10.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.81M | $3.76M | $978.74K | $5.79M | +1.3% |
| Cash & short-term investments | $3.81M | $3.76M | $978.74K | $5.79M | +1.3% |
| Accounts receivable | $3.42M | $3.77M | $2.19M | $1.76M | -9.3% |
| Inventory | $9.27M | $7.11M | $7.81M | $6.04M | +30.3% |
| Total current assets | $16.94M | $15.04M | $11.47M | $13.99M | +12.6% |
| Property, plant & equipment | $25.45M | $29.91M | $32.15M | $30.64M | -14.9% |
| Goodwill & intangibles | $95.56K | $114.66K | $133.76K | $152.87K | -16.7% |
| Total assets | $42.53M | $45.10M | $43.81M | $44.86M | -5.7% |
| Total current liabilities | $3.98M | $4.41M | $4.20M | $3.07M | -9.8% |
| Current debt | $1.61M | $1.50M | $1.43M | $1.04M | +7.5% |
| Long-term debt | $7.49M | $9.04M | $10.54M | $9.19M | -17.2% |
| Total debt | $13.19M | $15.10M | $16.69M | $12.48M | -12.6% |
| Total liabilities | $15.48M | $17.58M | $18.82M | $14.48M | -12.0% |
| Retained earnings | -$15.20M | -$14.16M | -$12.01M | -$6.23M | -7.3% |
| Shareholder equity | $27.06M | $27.52M | $24.99M | $30.38M | -1.7% |
| Working capital | $12.97M | $10.63M | $7.27M | $10.92M | +22.0% |
| Net tangible assets | $26.96M | $27.40M | $24.86M | $30.23M | -1.6% |
| Shares issued | 9.11M | 9.04M | 7.81M | 7.81M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.04M | -$2.16M | -$5.77M | -$2.49M | +51.8% |
| Depreciation & amortisation | $2.73M | $2.69M | $2.72M | $2.49M | +1.6% |
| Stock-based compensation | $295.87K | $325.55K | $368.87K | $266.24K | -9.1% |
| Change in working capital | -$2.05M | -$406.52K | -$2.11M | -$1.83M | -405.0% |
| Operating cash flow | $2.48M | $357.90K | -$4.67M | -$1.54M | +591.6% |
| Capital expenditure | -$1.25M | -$465.73K | -$1.89M | -$3.98M | -168.5% |
| Investing cash flow | -$1.21M | -$461.23K | -$1.89M | -$3.96M | -163.3% |
| Financing cash flow | -$1.21M | $2.88M | $1.75M | $1.11M | -142.1% |
| Free cash flow | $1.22M | -$107.82K | -$6.57M | -$5.52M | +1,236.0% |
| End cash position | $3.81M | $3.76M | $978.74K | $5.79M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.19M | $10.36M | $7.63M | $5.51M | $6.44M | -30.6% |
| Operating revenue | $7.19M | $10.36M | $7.63M | $5.51M | $6.44M | -30.6% |
| Cost of revenue | $4.75M | $5.70M | $4.72M | $3.14M | $3.63M | -16.7% |
| Gross profit | $2.44M | $4.66M | $2.91M | $2.36M | $2.82M | -47.7% |
| Research & development | $119.65K | $317.69K | $758.86K | $694.31K | $831.86K | -62.3% |
| Selling, general & admin | $2.38M | $2.37M | $2.21M | $1.65M | $1.42M | +0.5% |
| Total operating expense | $502.29K | $2.69M | $2.97M | $2.34M | $2.25M | -81.3% |
| Operating income | $1.93M | $1.97M | -$57.96K | $20.07K | $569.56K | -1.7% |
| Net interest income | -$30.32K | -$55.31K | -$74.49K | -$93.05K | -$76.68K | +45.2% |
| Pre-tax income | $1.88M | $1.95M | -$2.85M | -$135.29K | $503.78K | -3.8% |
| Tax provision | $45.95K | $12.52K | $3.31K | $4.46K | $1.90K | +267.0% |
| Net income | $1.83M | $1.94M | -$2.85M | -$139.75K | $501.88K | -5.5% |
| Net income to common | $1.83M | $1.94M | -$2.85M | -$139.75K | $501.88K | -5.5% |
| Basic EPS | 0.20 | 0.21 | -0.31 | -0.02 | 0.06 | -4.8% |
| Diluted EPS | 0.20 | 0.21 | -0.31 | -0.02 | 0.06 | -4.8% |
| EBIT | $1.97M | $2.05M | -$2.74M | -$30.35K | $617.77K | -3.8% |
| EBITDA | $2.44M | $2.58M | -$2.04M | $648.73K | $1.29M | -5.2% |
| Basic shares | 9.06M | 9.05M | 9.05M | 9.05M | 9.03M | +0.2% |
| Diluted shares | 9.19M | 9.05M | 9.05M | 9.05M | 9.03M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.86M | $6.81M | $3.81M | $3.89M | $6.00M | +30.1% |
| Cash & short-term investments | $8.86M | $6.81M | $3.81M | $3.89M | $6.00M | +30.1% |
| Accounts receivable | $2.90M | $2.69M | $3.42M | $2.55M | $2.38M | +7.5% |
| Inventory | $9.08M | $8.67M | $9.27M | $9.80M | $8.29M | +4.7% |
| Total current assets | $21.08M | $18.86M | $16.94M | $16.83M | $17.14M | +11.8% |
| Property, plant & equipment | $25.42M | $25.12M | $25.45M | $28.76M | $29.43M | +1.2% |
| Goodwill & intangibles | $95.56K | $95.56K | $95.56K | $100.33K | $105.11K | 0.0% |
| Total assets | $46.63M | $44.11M | $42.53M | $45.73M | $46.72M | +5.7% |
| Total current liabilities | $4.44M | $3.91M | $3.98M | $4.00M | $4.45M | +13.4% |
| Current debt | $1.51M | $1.63M | $1.61M | $1.59M | $1.54M | -7.5% |
| Long-term debt | $6.80M | $7.07M | $7.49M | $7.90M | $8.26M | -3.9% |
| Total debt | $12.45M | $12.78M | $13.19M | $13.61M | $14.27M | -2.6% |
| Total liabilities | $15.26M | $14.97M | $15.48M | $15.93M | $16.85M | +1.9% |
| Retained earnings | -$11.43M | -$13.26M | -$15.20M | -$12.35M | -$12.21M | +13.8% |
| Shareholder equity | $31.37M | $29.14M | $27.06M | $29.80M | $29.87M | +7.7% |
| Working capital | $16.64M | $14.95M | $12.97M | $12.83M | $12.69M | +11.3% |
| Net tangible assets | $31.28M | $29.04M | $26.96M | $29.70M | $29.76M | +7.7% |
| Shares issued | 9.08M | 9.11M | 9.11M | 9.11M | 9.10M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.83M | $1.94M | -$2.85M | -$139.75K | $501.88K | -5.5% |
| Depreciation & amortisation | $470.62K | $528.29K | $706.32K | $679.09K | $668.23K | -10.9% |
| Stock-based compensation | $239.87K | $137.95K | $103.78K | $73.16K | $66.71K | +73.9% |
| Change in working capital | $450.72K | $946.23K | -$215.02K | -$1.66M | $399.77K | -52.4% |
| Operating cash flow | $3.02M | $3.57M | $482.54K | -$1.18M | $1.60M | -15.5% |
| Capital expenditure | -$733.94K | -$177.23K | -$172.31K | -$593.92K | -$155.16K | -314.1% |
| Investing cash flow | -$733.94K | -$167.23K | -$167.31K | -$592.02K | -$125.93K | -338.9% |
| Financing cash flow | -$237.56K | -$400.00K | -$394.60K | -$337.69K | -$76.45K | +40.6% |
| Free cash flow | $2.29M | $3.40M | $310.24K | -$1.78M | $1.45M | -32.7% |
| End cash position | $8.86M | $6.81M | $3.81M | $3.89M | $6.00M | +30.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2020 | -0.04 | 0.03 | +175.0% |
| Sep 2020 | -0.08 | -0.04 | +50.0% |
| Jun 2020 | -0.10 | -0.11 | -10.0% |
| Mar 2020 | — | -0.02 | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders32.09%
Held by institutions20.30%
Institutions holding35
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.86
+1.14% from price
SMA 20
9.86
+1.11% from price
SMA 50
10.19
-2.12% from price
SMA 100
10.19
-2.19% from price
SMA 200
8.49
+17.39% from price
EMA 12
9.85
+1.21% from price
EMA 26
9.93
+0.43% from price
EMA 50
10.01
-0.43% from price
RSI (14)
51.2
Neutral
MACD (12,26,9)
-0.08
Hist 0.01
ATR (14)
0.27
2.69% of price
Realised vol 30D
20.3%
Annualised
Bollinger upper
10.15
20, 2σ
Bollinger lower
9.57
20, 2σ
50 / 200 cross
Golden
10.19 vs 8.49
Trend bias
Above 200
+17.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.36
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
20.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.9%
Peak to trough
Max drawdown 5Y
-67.0%
Peak to trough
ATR 14
0.27
2.69% of price
Beta (reported)
0.57
5Y monthly, from filing
Short interest
Shares short
19.83K
Prior 15.22K
Change vs prior
+30.2%
Shorts adding
% of float
0.26%
Normal
% of shares out
0.22%
Against total outstanding
Days to cover
0.8
Liquid
Float
6.03M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 20 | Aegis Capital | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:100
Split dateJul 25, 1990
SEC filings
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-09
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-14
Periodic Financial Reports
10-K/A · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-08
Proxy Statements
DEF 14A · 2026-04-24
Headlines
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
Zacks · 8d ago
Top Research Reports for Alphabet, Mastercard & AbbVie
Zacks · 9d ago
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
Zacks · 41d ago
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...
GuruFocus.com · 53d ago
ImmuCell Q2 Earnings Call Highlights
MarketBeat · 54d ago
ImmuCell Corporation Q2 2026 Earnings Call Summary
Moby · 54d ago
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
GlobeNewswire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.